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ABSTRACT
The Effect of Recombinant Human Bone Morphogenetic Protein-2 on the
Osseointegration of Temporary Anchorage Devices
Eden E. Cruz

Titanium has been widely used for dental implants, and in particular, roughened
titanium surfaces have provided a means for increasing bone apposition and
strengthening the implant-to-bone interface. Finding a way to further increase
osseointegration is important because there is a significant clinical benefit to patients if a
stable anchor can be established instead of anchoring orthodontic hardware to the molars.
In this study, the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2)
on the ability of temporary anchorage devices (TADs) to osseointegrate was investigated.
The temporary anchorage devices (TADs) used in this study were manufactured from
commercially pure titanium and divided into 2 types of treatments: (1) sandblasted and
acid-etched (i.e. the control) and (2) sandblasted and acid-etched treated with Medtronic
INFUSE® Bone Graft (recombinant human bone morphogenetic protein-2 placed on an
absorbable collagen sponge). The implants were placed on the cranial bones of 10 adult
male Sprague-Dawley rats. The rats were euthanized by carbon dioxide asphyxiation 6
weeks following surgery for histological examination and biomechanical testing. The
results from visual inspection and biomechanical testing showed that the sandblasted and
acid-etched TADs treated with rhBMP-2 promoted better osseointegration than TADs
that were only sandblasted and acid-etched. Specifically, surface modified TADs treated
with rhBMP-2 on bottom showed an increased surface coverage by bone and an increase
in the adhesion strength at the TAD-to-bone interface.
Key Words: temporary anchorage device, sand-blasted and acid-etched surface, rhBMP2, butyl cyanoacrylate, osseointegration
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1. LITERATURE REVIEW
With the objective of replacing missing teeth for patients, titanium implants have
continued to play an important role in the dental industry since the time when Dr. Per
Ingvar Branemark discovered titanium’s biocompatibility and its ability to integrate into
bone in the 1960’s. Specifically, the use of titanium implants as temporary anchorage
devices (TADs) has been a significant application in orthodontic practice for the past 5
years. As an alternative to using molars as anchors, which may lead to undesired teeth
movement, these TADs offer orthodontists the ability to move teeth against fixed objects
instead of against neighboring teeth, thus avoiding the equal and opposite reaction forces
as described by Newton’s third law [1, 2].

Although TADs offer orthodontists unparalleled opportunities to move specific
teeth while avoiding undesired movement of the surrounding teeth, they also present
potential danger to patients. Possible risks and complications that may occur if an
insufficient amount of bone is available at the implant site include root trauma, soft-tissue
irritation, nerve injury, sinus perforation, and damage of maxillary and mandibular
neurovascular systems [3, 4]. Presently, TADs vary from 5 to 12 mm in length and 1.3 to
2 mm in diameter, and thus, there is no practical way to attach a TAD and maintain
mechanical retention without piercing the bone. Unfortunately, this could lead to the
risks that were previously mentioned. Not only does a bone piercing TAD run the risks
of possible side effects, it also introduces implant site limitations. In order to avoid root
trauma, a bone piercing TAD would have to be inserted between the roots. If it were
possible to attach a TAD as close to the surface of the bone as possible (just under the
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periosteum) without piercing it, then serious side effects and insertion site limitations
may be avoided.

To tackle the issue of bone height and bone piercing, Block and Hoffman
developed the “onplant,” which is a disk-like hydroxyapatite-coated structure
approximately 10 mm in diameter and 2mm in height. The onplant is usually located
subperiosteally on the posterior portion of the hard palate, and with a transpalatal arch,
the onplant is attached to the orthodontic bands on the upper molar teeth [5]. According
to Block and Hoffman, this mechanism has been shown to resist greater than 300 g of
continuous orthodontic force [5]. Therefore, the onplant provides maximum anchorage
to the molars and total anchorage for tooth movement without reciprocal movement of
the onplant [1, 4]. Unfortunately, the surgical procedures for removing the onplant are
intricate and involve re-exposing a large portion of soft tissue, which can be distressing
for the patient. Advancement in the safety of TADs and minimal discomfort for patients
would be available if bone piercing and painful removal procedures could be prevented.
Should surface TADs be considered?

Surface TADs seem to address the potential side effects involved with bone
piercing, but like bone piercing TADs, surface TADs present limitations that are worth
considering. Unlike bone piercing TADs that are long and wide and can provide
mechanical retention, surface TADs lack mechanical retention. Without this mechanical
retention, the ability to achieve absolute anchorage is minimal. If it were possible to
strengthen the interface between the TAD and bone, then orthodontic anchorage may be
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established. During the 1960’s, Dr. Per Ingvar Branemark introduced the phenomenon of
“osseointegration,” which meant the direct structural and functional connection between
living bone and the surface of a load-bearing implant [1, 6]. Through experimentation,
Branemark found that titanium itself integrates into bone. Titanium microscope heads
placed into the thighbone of a rabbit could not be taken out during the removal process
because the titanium oxide at the surface of the microscope heads had permanently fused
with the bone. If it were possible to use titanium as the implant material for TADs, then
mechanical retention and a stable anchor could be obtained.

Titanium has been used for artificial hip joints for many years, and unlike other
alloys, titanium has been shown to be biocompatible with the human body. In addition to
its biocompatibility, titanium is lightweight, strong, corrosion and fracture resistant, has
low thermal conductivity, and can be machined and formed easily [7, 8]. Furthermore, its
titanium oxide layer allows the direct contact between a titanium implant surface and
bone (i.e. osseointegration). While stainless steel has also been used in orthodontics
because of its high strength, it cannot be shaped easily like titanium because of its high
linear coefficient of thermal expansion. In addition, stainless steel’s high nickel content
makes stainless steel less desirable in terms of biocompatibility because nickel is not
biocompatible. Therefore, titanium, with its excellent biocompatibility, is the more
desirable choice for implant material.

Taking it a step further, not only is the implant material important, but the implant
surface itself is also a critical factor in promoting osseointegration [9, 10, 11, 12]. For
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example, titanium surfaces with microscale roughness have been shown to enhance
osseous apposition by increasing the total surface area available for bone formation. In
particular, a combination of sandblasting and acid-etching techniques has been effective
in producing these microrough titanium surfaces [10, 11]. Implants with sandblasted and
acid-etched surfaces have increased osteoblastic attachment and differentiation, which in
turn, have strengthened bone implant contact and enhanced removal torque values in
biomechanical testing.

Currently, sandblasted and acid-etched surfaces are considered a high standard of
treatment for titanium implants, but is there a way to improve surface modifications to
further increase osseointegration and implant stability? If additional modifications can be
made to the TAD surface, the TAD can act as a stable anchor while eliminating the need
to puncture the bone. By finding a way to further enhance osseointegration, the surface
modification necessary for optimal bone apposition and optimal quality of the bone-TAD
interface can be achieved.

The use of bone morphogenetic protein (BMP) can be a means of achieving the
desired surface modifications. BMPs are a group of growth factors, which for decades
now, have been studied and investigated because of their ability to induce bone and
cartilage formation [13, 14, 15, 16]. BMPs have demonstrated the ability to heal bone,
which in turn, has eliminated the need for bone harvesting from other parts of the body.
Since its discovery in the 1960s by Urist, so far, approximately 20 BMPs have been
identified and characterized. Of these twenty BMPs, BMPs 2-9 belong to the
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transforming growth factor-β (TGF–β) superfamily. Within this TGF–β superfamily, two
members in particular, BMP-2 and BMP-7, have become the subject of extensive
research. Exhibiting great osteogenic capacity, BMP-2 and BMP-7 have the ability to
radically induce osteoblast differentiation in a variety of cell types and their significance
in bone development is supported in various experimental studies [15, 17]. Furthermore,
BMP-2 and BMP-7 have shown great potential in therapeutic applications, specifically in
the treatment of bone-related conditions and defects.

From the time BMPs were first discovered, their importance in healing bone and
stimulating bone growth within the body has been undeniable. When BMPs were
discovered more than 40 years ago, they were naturally occurring within the bone matrix
itself. However, for the first time in 1988, these naturally occurring proteins were isolated
and genetically reproduced to form recombinant human bone morphogenetic protein, or
rhBMP. Like the naturally occurring protein, the recombinant form, according to several
preclinical studies, has demonstrated the ability to induce new bone growth [16, 18, 19,
20]. Specifically, rhBMP-2 has been studied more than any other BMP and has been
approved by the Food and Drug Administration (FDA) for use in tibial, oral, and spinal
surgical procedures. Furthermore, studies have shown that when rhBMP-2 is used with a
carrier, for example a collagen sponge, it has the ability to improve spinal fusion,
increase periodontal new bone formation, and encourage fracture repair. In addition,
rhBMP-2 has been used to regenerate defects of the mandible and skull, and help in the
treatment of non-union, delayed union, and other skeletal conditions [13, 15, 18, 19].
Clearly, rhBMP-2 has been effective in several types of applications and therefore is
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chosen for this current study. In particular, Medtronic INFUSE® Bone Graft, which uses
an absorbable collage sponge (ACS) as a carrier for the rhBMP-2, is used.

Medtronic INFUSE® Bone Graft has been used in various applications and has
the capability of facilitating bone growth in different parts of the body. In tibial fractures,
it has aided in the healing of broken bones, and in the spine, it has helped minimize back
pain and maximize spine stability by allowing the vertebrae to fuse. Moreover, Medtronic
INFUSE® Bone Graft has helped in localized alveolar ridge augmentation and sinus
augmentation, types of maxillofacial and oral grafting procedures.

Recombinant human bone morphogenetic protein-2 has great potential in
facilitating new bone growth and promoting enhanced osseointegration, but its ability to
do so relies greatly on implant stabilization. The ability of a TAD to osseointegrate is
compromised when implant stabilization is not present because the potential for
microfractures at the bone-TAD interface increases. Osseointegration does not occur
instantly, and thus, during this waiting period, it is critical to find a way to stabilize the
TAD. This is very important because a “loose” TAD could influence the effectiveness of
the rhBMP-2.

In orthodontic practices, the screw TAD has been one solution to achieving
implant stabilization [1, 4, 5]. The screw TAD has been widely used because of its ability
to generate static equilibrium. In other words, the sum of all the forces and the sum of all
the moments about a point is zero [1]. Screw TADs, which are threaded into bone, create
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mechanical resistance so that implant stability can occur. The problem with screw TADs,
however, is that it involves puncturing of the bone. This defeats the purpose of the study
which is to eliminate puncture of the bone while promoting enhanced osseointegration.
Therefore, another method aside from screw TADs must be considered to achieve desired
implant stability.

The use of cyanoacrylate, or “tissue glue,” can be a means of stabilizing the TAD
without having to puncture the bone. Cyanoacrylates have been used in a variety of
applications ranging from the manufacture of electronics, shoes, and sports equipment, to
areas of dentistry and surgery [21]. As a whole, cyanoacrylates have been very useful in
general and medical applications. Cyanoacrylate tissue adhesives have been shown to
have similar results to suturing and to be a considerably faster method of skin edge
apposition in small facial lacerations [22]. In fact, it has been used to seal wounds and
stop bleeding since the time of the Vietnam War. More specifically, there are several
types of cyanoacrylates, which include methyl, ethyl, butyl, and octyl cyanoacrylate. In
most cases, the type of cyanoacrylate that is used depends on the specific application.
Methyl cyanoacrylate, for example, works well for metal bonding applications, whereas
ethyl cyanoacrylate works well for bonding plastics, metals, and rubber. Butyl
cyanoacrylate is notable for bonding tissues and can be used as an alternative to suturing
[22, 23]. Finally, octyl cyanoacrylate is useful for surface wound healing. In general,
cyanoacrylates are useful because they have fast curing times. Implant stability is
essential for osseointegration to occur. Cyanoacrylates provide a way to avoid damage to
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the bone and increase the likelihood of osseointegration by creating a stable temporary
anchorage device.
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2. RESEARCH & SPECIFIC AIMS
2.1 Objective
Titanium has been widely used for dental implants, and in particular, roughened
titanium surfaces (i.e. sandblasted and acid-etched) have provided a means for
accelerating osseointegration and strengthening the bone-implant interface. The goal of
this study is to determine the effect of recombinant human bone morphogenetic protein-2
(rhBMP-2), or more specifically, Medtronic INFUSE® Bone Graft, on the ability of
temporary anchorage devices (TADs) to osseointegrate. In particular, this study will
determine the influence of rhBMP-2 in addition to a sandblasted and acid-etched surface
on implant anchorage and increased bone formation. Finding a way to increase
osseointegration is important because there is a significant clinical benefit to patients if a
stable anchor can be established instead of anchoring orthodontic hardware to the molars.
Moreover, increasing osseointegration of surface TADs would ideally minimize
interfacial movement, prevent slip, and increase long-term implant stability without
piercing the bone.

2.2 Specific Aim
To investigate the influence of recombinant human bone morphogenetic protein-2
(rhBMP-2) on the osseointegration of temporary anchorage devices (TADs). This will
involve qualitative examination of the TAD surface covered by bone through the means
of visual inspection and photographs. The surface coverage of a sandblasted/acidetched/rhBMP-2 treated TAD will be compared to the surface coverage of a control
specimen (a sandblasted and acid-etched titanium TAD). In addition, mechanical testing
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will be done to determine if the rhBMP-2 treatment on the TAD produces any significant
changes in the bond strength between the bone and TAD.

2.3 Hypothesis
Sandblasted and acid-etched temporary anchorage devices (TADs) treated with
recombinant human bone morphogenetic protein-2 (rhBMP-2) will promote better
osseointegration than TADs that are only sandblasted and acid-etched. Specifically,
surface modified TADs treated with rhBMP-2 on bottom will show an increased surface
coverage by bone and an increase in the adhesion strength at the bone-to-TAD interface.
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3. MATERIALS & METHODS
3.1 Rationale for Species & Numbers
Ten adult male Sprague-Dawley rats (4 controls and 6 treated with the absorbable
collagen sponge/rhBMP-2 mixture) with average weight of 359 ± 108 g were used for
this study and handled in accordance with an IACUC approved protocol and with the
National Institutes of Health (NIH) guidelines for the care and use of laboratory animals
(NIH publication 85-23, Rev. 1985). Specifically, Simonsen albino adult male rats were
chosen for this study. In addition, the number of rats was calculated using the 1-Sample t
test to ensure that a sufficient amount of data would be produced while limiting the
number of rats used.

The Sprague-Dawley rat was selected as the appropriate species of

choice due to its genetic similarity to humans and its ability to serve as a general model
for the study of human health and disease. Sprague-Dawley rats are widely used for
experimental purposes, and in particular, their calmness and ease of handling make them
the choice of species for this study. Studies similar to this current study have shown
sound scientific results with the use of Sprague-Dawley rats.

3.2 Surgical Procedures
3.2.1 Introduction
The details of each rat surgery, such as time of injection, initiation of surgery,
monitoring of rat vitals, and completion time of surgery are recorded in a lab notebook.
See Appendix A for a copy of this raw data. The surgical procedures are based on the
results of preliminary experiments (Appendix B). To ensure that each surgery was
performed smoothly for each animal, the surgery checklist in Appendix C was used.
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3.2.2 Implant Preparation
The temporary anchorage devices (TADs) used in this study were manufactured
from commercially pure titanium and divided into 2 types of treatments: Type 1 was
sandblasted (with grit) and acid-etched (combination of anorganic acids, HCl/H2SO4 acid
bath), and Type 2 was treated with Medtronic INFUSE® Bone Graft (recombinant
human bone morphogenetic protein-2 placed on an absorbable collagen sponge) in
addition to a sandblasted and acid-etched treatment. Type 1 treated surfaces served as the
control TADs for this study because previous studies have shown that the combination of
sandblasting and acid-etching is a high standard of treatment for titanium that creates a
modified surface topography and allows for enhanced bone apposition and bone implant
contact. An absorbable collagen sponge soaked in saline was used for the control TAD in
order to reduce the variability of the results and focus solely on the effect of the rhBMP-2
on the osseointegration of the TAD. Type 2 treated surfaces were also sandblasted and
acid-etched, but had an additional treatment of Medtronic INFUSE® Bone Graft on
bottom in order to determine if rhBMP-2 improves on the already working technology
(sandblasted and acid-etched treatment).

For a Type 1 TAD, a 1 cm x 1 cm absorbable collagen sponge (ACS) was treated
with 0.09 cc of saline using a sterile syringe and sterile tray. Refer to Figure 3.1.
Similarly, for a Type 2 treated TAD, a 1 cm x 1 cm absorbable collagen sponge was
treated with 0.09 cc of reconstituted rhBMP-2 using a sterile syringe and sterile tray. The
absorbable collagen sponge with either saline or rhBMP-2 was set for at least 15 minutes
before use.
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Figure 3.1 1 cm x 1 cm ACS treated with 0.09 cc of saline

3.2.3 Pre-Operative
The dosages administered to the Sprague-Dawley rats for general anesthesia and
pain medication were based on the weight of the animal. A mixture of Ketamine and
Xylazine (44 mg/kg body weight of Ketamine, 10 mg/kg body weight of Xylazine) was
used for inducting general anesthesia. This provided approximately 30 minutes of
effective anesthesia. In addition, a dose of Buprenorphine was administered
subcutaneously (0.01 – 0.05 mg/kg body weight) between the shoulder blades for pain
mitigation. Refer to Appendix D for the table of weights and the respective dosages for
Ketamine, Xylazine, and Buprenorphine. The dosages were recorded in a lab notebook
which is under lock and key at the California Polytechnic State University, San Luis
Obispo surgical suite. The Ketamine/Xylazine and Buprenorphine mixture worked well
because emergence from anesthesia was smoother and had a high factor of safety. Under
anesthesia, the rat did not respond to various audible and tactic stimuli, but maintained
normal breathing and heart rate. Once the rat was in Stage 3 and the anesthesia had taken
effect, the rat was ready to undergo prepping procedures.
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For surgery, the rat was prepped by shaving the surgical site (rat’s head), applying
depilatory cream to remove excess hair, and disinfecting the area with Betadine solution
using sterile cotton swabs applied in a circular motion. This process was preformed 3
times (with 3 different cotton swabs), and the antiseptic was in contact with the skin for a
minimum of 3 minutes before incision. Prior to surgery, a sterile surgical drape was put
over the animal to ensure that aseptic standards were met.

3.2.4 Operative
Using the “tips-only” technique, an incision was made along the midline of the
head from the eyes to the ears. Once the incision was made, the periosteum was carefully
held back to expose the bony complex on the surface of the cranium. Sterile forceps
were used to pick up a temporary anchorage device and place it on the surface of the
cranial bone (either on the frontal or parietal bone) in order to contour it to fit the shape
of the animal’s skull. A sterile instrument was used to place the collagen sponge (wet
with saline or rhBMP-2) on the rat skull before placing the TAD on top of it and
stabilizing the TAD with butyl cyanoacrylate. The butyl cyanoacrylate took
approximately 2 minutes to set. While surgery was in progress, the animal’s vital signs
were continually monitored. Once the implant was in place, the incision was closed
using butyl cyanoacrylate.

3.2.5 Post-Operative
After surgery and the removal of the surgical drape, the rat was moved to a warm
area (recovery bin) where it was monitored during recovery. A heating pad was used to
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return the animal’s body temperature back to normal. Upon full recovery from the
anesthesia, the rat was returned to its routine housing; each rat was caged separately.
Buprenorphine (0.01 -0.05 mg/kg) was administered 3 times a day for 2 days as
necessary for pain management. In the event of an infection, the wound site was cleaned
2 times/day with Betadine solution. The rats were visually inspected daily post-op for
infection, and a surgical record (procedure, date, anesthesia dose, route of administration)
was maintained. The rats were euthanized by carbon dioxide asphyxiation 6 weeks after
surgery for histological evaluation and biomechanical testing.

3.3 Histological Evaluation
After the rats were euthanized by carbon dioxide asphyxiation, a qualitative
analysis was performed. Qualitative analysis included examining surface topography and
the amount of the TAD surface covered by bone through photographs and visual
inspection. A comparison of surface topography and TAD coverage was made between
the rhBMP-2 treated TAD and the control specimen (sandblasted and acid-etched TAD).

3.4 Biomechanical Testing
3.4.1 Proof of Experimental Concept
As proof of experimental concept, the shear strength of the orthodontic implant
was mechanically tested using a polyurethane block. The test involved imbedding the
device onto a polyurethane 20 lb foam block and attaching it to a micromechanical
testing system (In Spec, Instron Corporation, Camden, MA) with a 50 N load cell (see
Figure 3.2). Five replicate tests were conducted with an average shear load of 8.9 ± 1.5
N.
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Figure 3.2 Proof of experimental concept

3.4.2 Test Setup for Biomechanical Testing
Biomechanical testing was performed using a micromechanical testing system (In
Spec, Instron Corporation, Camden, MA). The rat head was secured in a chuck in
preparation for biomechanical testing. A string was attached from the protruding part of
the TAD to the Instron machine. Refer to figures 3.3 and 3.4. To test initial stability of
the temporary anchorage device, load was applied to the upper part of each TAD in the
shear direction (right angle to an implant) with a force at constant speed until the
surrounding bone was destroyed.
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Figure 3.3 Biomechanical test setup

Figure 3.4 Applying load in the shear direction with a force at constant speed
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4. RESULTS
4.1 TAD Bone Coverage

Rat #
Rat 4
Rat 8
Rat 12
Rat 13
Rat 14
Rat 15
Rat 16
Rat 17
Rat 18
Rat 20
Rat 25

Table 4.1 TAD bone coverage
Control or rhBMP-2 treated
Bone Coverage
Bone coverage observed; however, data
Control, sponge on bottom
discarded as TAD was left in rat for over 6
weeks
Control, sponge on bottom
10% bone coverage
Sponge on bottom w/ rhBMP-2
35% bone coverage
Control, sponge on bottom
20% bone coverage
Sponge on bottom w/ rhBMP-2
40% bone coverage
Sponge on bottom w/ rhBMP-2
80% bone coverage
Control, sponge on bottom
15% bone coverage
Sponge on bottom w/ rhBMP-2
45% bone coverage
Sponge on bottom w/ rhBMP-2
95% bone coverage
No bone coverage observed – TAD stuck to
Control, sponge on bottom
soft tissue
Sponge on bottom w/ rhBMP-2
30% bone coverage

The raw data (photographs of TAD bone coverage) for each rat is found in Appendix E.
The TAD bone coverage summary, including mean and standard deviation, is represented
in Figure 4.1 below.

TAD Bone Coverage Summary
% Bone Coverage
of TAD

Control TAD versus rhBMP-2 treated TAD

90
80
70
60
50
40
30
20
10
0

Treatment 1
(control) mean +
st.dev
Treatment 2
(rhBMP-2) mean +
st.dev
Treatment Type
Figure 4.1 TAD bone coverage summary
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4.2 Biomechanical Testing: Failure Load

Rat #
Rat 4
Rat 8
Rat 12
Rat 13
Rat 14
Rat 15
Rat 16
Rat 17
Rat 18
Rat 20
Rat 25

Table 4.2 Biomechanical testing: measuring failure load
Control or rhBMP-2 treated?
Failure Load
8.38 N - Data discarded as TAD was left in
Control, sponge on bottom
rat for over 6 weeks
Control, sponge on bottom
2.56 N
Sponge on bottom w/ rhBMP-2
5.13 N
Control, sponge on bottom
4.53 N
Sponge on bottom w/ rhBMP-2
15.12 N
Sponge on bottom w/ rhBMP-2
32.72 N
Control, sponge on bottom
2.84 N
Sponge on bottom w/ rhBMP-2
7.03 N
Sponge on bottom w/ rhBMP-2
84.47 N
Control, sponge on bottom
0 N – TAD was loose and stuck to soft tissue
Sponge on bottom w/ rhBMP-2
11.29 N

The failure load graph (i.e. force-displacement curve) for each rat is found in Appendix
F. The failure load summary, including mean and standard deviation, is represented in
Figure 4.2 below.

Biomechanical Testing: Failure Load Summary

Failure load (N)

Control TAD versus rhBMP-2 treated TAD

60
50
40
30
20
10
0
-10

Treatment 1
(control) mean
+ st.dev
Treatment 2
(rhBMP-2)
mean + st.dev
Treatment Type

Figure 4.2 Biomechanical testing: failure load summary
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5. DISCUSSION
5.1 TAD Bone Coverage
Bone coverage was present on all rhBMP-2 treated TADs and all but one of the
control TADs. This observation was made through visual inspection and photographs
taken prior to biomechanical testing. For the control TAD in Rat #20, no bone coverage
was observed because the TAD had lost contact with the bone sometime during the 6
week implantation. It is most likely that the TAD had become loose early on before any
osseointegration could be achieved. The TAD may have gotten loose because an
insufficient amount of butyl cyanoacrylate was used to secure the TAD to the bone.

In addition, through visual inspection and photographs, it was discovered that the
TADs that had been treated with rhBMP-2 showed significantly more bone coverage than
the control TADs. The rhBMP-2 treated TADs and the control TADs both have a
sandblasted and acid-etched surface, which alone has been shown to facilitate bone
growth. However, with the additional rhBMP-2 surface treatment, the TADs showed
even better osseointegration and percent TAD surface covered by bone. Specifically, the
average % bone coverage of the control TADs was 11.25 ± 8.54%, while the average %
bone coverage of the rhBMP-2 treated TADs was 54.17 ± 26.72%. The % TAD bone
coverage summaries (assuming 95% confidence) for Treatment 1 (control) and Treatment
2 (rhBMP-2) are represented in figures 5.1 and 5.2 below. These summaries show that
the 95% confidence intervals for the mean are (-2.338, 24.838) and (26.122, 82.212) for
the control TADs and rhBMP-2 treated TADs respectively. The lower limit of 26.12%
bone coverage for the rhBMP-2 treated TAD is greater than the upper limit of 24.84%
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bone coverage for the control TAD. Therefore, for 95% of the time, an rhBMP-2 treated
TAD will show greater % surface coverage by bone than a control TAD.

Summary for Treatment 1 (Control)
A nderson-D arling N ormality Test
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P -V alue
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0.342857
4

M inimum
1st Q uartile
M edian
3rd Q uartile
M aximum
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Figure 5.1 TAD bone coverage summary for treatment 1 (control)
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31.839

Summary for Treatment 2 (rhBMP-2)
A nderson-Darling N ormality Test
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Figure 5.2 TAD bone coverage summary for treatment 2 (rhBMP-2)

5.2 Strength at TAD/Bone Interface
The failure loads for the TADs treated with rhBMP-2 were significantly higher
than the failure loads for the control TADs. On average, the force needed to pull a control
TAD off the bone was 2.48 ± 1.87 N, while the average force needed to pull an rhBMP-2
treated TAD off the bone was 25.96 ± 30.31 N. The failure load summaries (assuming
95% confidence) for Treatment 1 (control) and Treatment 2 (rhBMP-2) are represented in
figures 5.3 and 5.4 below.
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Summary for Treatment 1 (Control)
A nderson-D arling N ormality Test

0

1

2

3

4

A -S quared
P -V alue

0.26
0.494

M ean
S tD ev
V ariance
S kew ness
Kurtosis
N

2.4825
1.8698
3.4963
-0.68011
1.65361
4

M inimum
1st Q uartile
M edian
3rd Q uartile
M aximum

5

0.0000
0.6400
2.7000
4.1075
4.5300

95% C onfidence Interv al for M ean
-0.4928

5.4578

95% C onfidence Interv al for M edian
0.0000

4.5300

95% C onfidence Interv al for S tD ev
9 5 % C onfidence Inter vals

1.0592

6.9718

Mean
Median
0

1

2

3

4

5

6

Figure 5.3 Failure load summary for treatment 1 (control)

Summary for Treatment 2 (rhBMP-2)
A nderson-D arling N ormality Test
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Figure 5.4 Failure load summary for treatment 2 (rhBMP-2)
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74.343

For the control TAD, the failure load of 0 N (data for Rat #20) was included. This
TAD had a failure load of 0 N because it had migrated or become loose sometime during
its 6 week implantation on the rat’s skull. When the rat’s skull was re-exposed to
investigate the results, it was found that the TAD was stuck to the soft tissue and no
longer had any contact with the bone. Thus, TAD stability was lost, preventing
osseointegration. The most likely reason for the TAD coming loose is that not enough
butyl cyanoacrylate was used to ensure TAD stability.

Taking a closer look at the measured failure load values for the rhBMP-2 treated
TADs, the values ranged anywhere from 5.13 N (minimum) to 84.47 N (maximum),
hence the large standard deviation and variance as indicated in Figure 5.4 (failure load
summary for Treatment 2 (rhBMP-2)). It is suspected that the variability in these values
is due to the stability of the TAD. The more stable the TAD, the greater the chance for
enhanced osseointegration. How stable the TAD is prior to osseointegration is dependent
on how well the butyl cyanoacrylate can “glue” the TAD to the bone. The absorbable
collagen sponge, which acted as the carrier for the rhBMP-2, was placed between the
TAD and the bone and made it even more challenging to stabilize the TAD with the
cyanoacrylate. In addition, the contour and shape of each rat skull varied, and therefore,
some TADs fit closer than others. All the factors mentioned above had an effect on how
much bone formed and how strong the TAD-to-bone interface was. The failure loads
varied between each TAD/rat even though the same procedure, test methods, and
materials were used. Despite the large variance in the failure load values for the rhBMP2 treated TADs, the minimum measured failure load value for the rhBMP-2 treated TAD
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of 5.13 N was still greater than the maximum failure load measured for the control TAD
of 4.53 N.

According to Figure 5.3, the 95% confidence interval for the mean failure load
for a control TAD is -0.4928 N to 5.4578 N. In addition, according to Figure 5.4, the
95% confidence interval for the mean failure load for an rhBMP-2 treated TAD is -5.850
N to 57.770 N. The confidence interval for the rhBMP-2 treated TAD shows that it is
possible that no osseointegration will occur for an rhBMP-2 treated TAD because the
failure load value could be 0 N (which lies between the lower and upper limits of the
confidence interval). In addition, it is possible that the failure load of an rhBMP-2 treated
TAD could be equal or similar to the failure load of a sandblasted and acid-etched
(control) TAD since their confidence intervals overlap at some point. Therefore, a
control TAD may osseointegrate just as well as an rhBMP-2 treated TAD. However, the
upper limit (with 95% confidence) for the rhBMP-2 treated TAD (57.770 N) is
approximately 10 times greater than the upper limit (with 95% confidence) for the control
TAD (5.4578 N). Thus, for 95% of the time, the failure load of the control TAD (even at
its maximum) is not likely to reach or exceed the potential adhesion strength of an
rhBMP-2 treated TAD. In this study, only one rhBMP-2 treated TAD, measuring 5.13 N
for its failure load, fell below the upper limit (5.4578 N) of the control TAD confidence
interval. Five of the six rhBMP-2 treated TADs achieved failure loads greater than the
upper limit of the control TAD confidence interval. Therefore, on average, the rhBMP-2
treated TADs showed an increase in the adhesion strength at the TAD-to-bone interface
when compared to the control (sandblasted and acid-etched) TADs.
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6. CONCLUSIONS
The results from visual inspection and biomechanical testing show that, on average,
the sandblasted and acid-etched temporary anchorage devices (TADs) treated with
recombinant human bone morphogenetic protein-2 (rhBMP-2) promote better
osseointegration than TADs that are only sandblasted and acid-etched. Specifically,
surface modified TADs treated with rhBMP-2 showed an increased % surface coverage
by bone and an increase in the adhesion strength at the TAD-to-bone interface.

Using TADs treated with rhBMP-2 promotes enhanced osseointegration which would
help increase long-term TAD stability without piercing the bone. By avoiding direct
insertion into the bone, this reduces the likelihood of developing bone infections.
Moreover, before osseointegration can be achieved, it is critical that TAD stability be
established. As evident in the results, this stability can be achieved using butyl
cyanoacrylate. By increasing osseointegration, TADs treated with rhBMP-2 can provide
a significant clinical benefit to patients by establishing a stable anchor and thus
eliminating the need to anchor orthodontic hardware to the molars.
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Appendix A
Data from Lab Notebook: Rat#, Surgery Details

Rat #
4

8

Table A.1 Surgical details from lab notebook
Date
Sponge Type
Time
Action
9/1/2008
Control, sponge
11:00am IP injection of 0.21cc Ketamine
on bottom
and 0.24cc Xylazine
Subcutaneous injection of 0.047cc
Buprenorphine and 15cc saline
11:20am Apply 0.09cc saline on collagen
sponge
11:21am Start incision
11:55am Surgery completed
1:32pm
Rat movement; began recovery
from anesthesia
9/2/2008
9:00am
Subcutaneous injection of 0.047cc
Buprenorphine
10/12/2008
11:00pm Euthanized by CO2 asphyxiation
10/4/2008

Control, sponge
on bottom

6:40am

6:50am
7:00am
7:20am
7:47am

12

10/5/2008

8:00am

11/15/2008

5:45pm

10/4/2008

Sponge on
bottom with
rhBMP-2

IP injection of 0.20cc Ketamine
and 0.23cc Xylazine
Subcutaneous injection of 0.046cc
Buprenorphine and 15cc saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.046cc
Buprenorphine
Euthanized by CO2 asphyxiation

3:02pm

Apply 0.09cc reconstituted BMP-2
on collagen sponge

3:08pm

IP injection of 0.19cc Ketamine
and 0.22cc Xylazine
Subcutaneous injection of 0.044cc
Buprenorphine and 15cc saline
Additional IP injection of 0.15cc
Ketamine and 0.15cc Xylazine
Start incision
Surgery completed
Rat movement; began recovery

3:40pm
4:15pm
4:41pm
6:00pm
30

Rat #
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Date

Sponge Type

Time

10/5/2008

8:05am

11/15/2008

5:55pm

10/4/2008

Control, sponge
on bottom

3:15pm

3:19pm
3:21pm
3:40pm
4:09pm
5:20pm

14

10/5/2008

8:08am

11/15/2008

5:55pm

10/4/2008

Sponge on
bottom with
rhBMP-2

4:19pm

4:29pm
4:30pm
4:56pm
4:59pm
5:15pm
6:30pm

15

10/5/2008

8:12am

11/15/2008

6:00pm

10/4/2008

Sponge on
bottom with
rhBMP-2

4:52pm

5:00pm

31

Action
from anesthesia
Subcutaneous injection of 0.044cc
Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.20cc Ketamine
and 0.23cc Xylazine
Subcutaneous injection of 0.046cc
Buprenorphine and 15cc saline
Apply 0.09cc saline on collagen
sponge
Additional IP injection of 0.15cc
Ketamine and 0.15cc Xylazine
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.046cc
Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.18cc Ketamine
and 0.20cc Xylazine
Subcutaneous injection of 0.044cc
Buprenorphine and 15cc saline
Apply 0.09cc reconstituted BMP-2
on collagen sponge
Additional IP injection of 0.15cc
Ketamine and 0.15cc Xylazine
Additional IP injection of 0.10cc
Ketamine and 0.10cc Xylazine
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.044cc
Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.15cc Ketamine
and 0.18cc Xylazine
Subcutaneous injection of 0.035cc
Buprenorphine and 15cc saline
Apply 0.09cc reconstituted BMP-2

Rat #

Date

Sponge Type

Time
5:20pm
6:00pm
7:45pm

16

10/5/2008

8:16am

11/15/2008

6:00pm

10/4/2008

Control, sponge
on bottom

8:48pm

8:55pm
9:00pm
9:17pm
10:40pm

17

10/5/2008

8:20am

11/15/2008

6:07pm

10/4/2008

Sponge on
bottom with
rhBMP-2

Apply 0.09cc reconstituted BMP-2
on collagen sponge

9:18pm

IP injection of 0.17cc Ketamine
and 0.19cc Xylazine
Subcutaneous injection of
0.0379cc Buprenorphine and 15cc
saline
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0379cc Buprenorphine
Euthanized by CO2 asphyxiation

10/5/2008

8:23am

11/15/2008

6:07pm

10/4/2008

Sponge on
bottom with
rhBMP-2

IP injection of 0.16cc Ketamine
and 0.18cc Xylazine
Subcutaneous injection of
0.0368cc Buprenorphine and 15cc
saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.035cc
Buprenorphine
Euthanized by CO2 asphyxiation

9:05pm

9:25pm
9:43pm
11:00pm

18

Action
on collagen sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of 0.035cc
Buprenorphine
Euthanized by CO2 asphyxiation

9:05pm

Apply 0.09cc reconstituted BMP-2
on collagen sponge

9:30pm

IP injection of 0.20cc Ketamine
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Rat #

Date

Sponge Type

Time

9:48pm
10:02pm
11:30pm

20

10/5/2008

8:25am

11/15/2008

6:15pm

10/5/2008

Control, sponge
on bottom

8:55am
8:56am

9:06am
9:22am
10:55am
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10/6/2008

8:00am

11/15/2008

6:30pm

2/7/2009

Sponge on
bottom with
rhBMP-2

4:05pm

4:10pm
4:15pm
4:10pm
5:00pm
2/8/2009

8:25am

3/21/2009

2:30pm

33

Action
and 0.23cc Xylazine
Subcutaneous injection of
0.0454cc Buprenorphine and 15cc
saline
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0454cc Buprenorphine
Euthanized by CO2 asphyxiation
Apply 0.09cc saline on collagen
sponge
IP injection of 0.17cc Ketamine
and 0.19cc Xylazine
Subcutaneous injection of
0.0377cc Buprenorphine and 15cc
saline
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0377cc Buprenorphine
Euthanized by CO2 asphyxiation
IP injection of 0.20cc Ketamine
and 0.20cc Xylazine
Subcutaneous injection of
0.0454cc Buprenorphine and 15cc
saline
Apply 0.09cc saline on collagen
sponge
Start incision
Surgery completed
Rat movement; began recovery
from anesthesia
Subcutaneous injection of
0.0454cc Buprenorphine
Euthanized by CO2 asphyxiation

Appendix B
Preliminary Experiments
B.1 Evaluating Butyl Cyanoacrylate
In the presence of moisture, cyanoacrylates rapidly polymerize and set quickly. A
quick and easy way to test whether a certain type of cyanoacrylate will adhere to tissue
with degrees of moisture is to apply the cyanoacrylate to designated sections of the
implant and see if it adheres to cow bone or fresh meat from the grocery store. The tissue
found in cow bone is similar to the tissue found in rats, and therefore using the cow bone
allows for quick and effective testing without having to perform surgery on the rat for
this preliminary step.

In addition, saliva added to the site of the implant accounts for the presence of
blood during the actual surgery. This aids in determining whether the saliva, with
chemical and physical components somewhat similar to blood, will have any effect on the
implant’s ability to adhere. From this experiment, the curing time and whether the
cyanoacrylate is an effective adhesive can be determined. Moreover, the effect of UV
light (which has been known to reduce curing time) will also be evaluated. Finding a way
to reduce the curing time is desired to ensure implant stability and to minimize the
amount of blood flow and other fluids into the implant site.
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An experiment using Vetbond butyl cyanoacrylate was performed. The results
from the experiment can be found in the following table:

Table B.1 Evaluating butyl cyanoacrylate
All trials used saliva to account for the presence of blood

Cow
Bone
New
York
Steak
Bone In
(Shaved
Bone)

Curing Time
Without UV
Light
(Trial 1)

Curing Time
Without UV
Light
(Trial 2)

2 minutes

2 minutes

1 minute, 50
seconds

1 minute, 55
seconds

2 minutes

2 minutes

1 minute, 50
seconds

2 minutes

Curing Time Curing Time
With UV
With UV
Light
Light
(Trial 1)
(Trial 2)

The curing time was determined based on the following graphs:
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Figure B.1 Adhesion strength vs. curing time (cow bone, no UV light)
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Figure B.2 Adhesion strength vs. curing time (NY steak, no UV light)
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Figure B.3 Adhesion strength vs. curing time (cow bone, UV light)
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Figure B.4 Adhesion strength vs. curing time (NY steak, UV light)
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Several conclusions were made from the above experiment:
•

Saliva does not affect the ability of the implant to adhere to bone. Thus, blood,
with chemical and physical components somewhat similar to blood, is also
assumed to have little effect on the ability of the implant to adhere to bone.

•

The curing time with UV light is less than the curing time without UV light.
However, the difference is not that significant.

B.2 Using the INFUSE® Bone Graft Sample Kit
Note: A buffer was used to substitute for the rhBMP-2 in the sample kit
Questions to be answered from the experiment:
•

Is it possible or necessary to separate the rhBMP-2 and sterile water into separate
vials for smaller samples? If so, how should this be done?

•

Is the effectiveness of the rhBMP-2 / sterile water mixture compromised if it is
not used all at one time?

•

What tools are necessary to cut the absorbable collagen sponge (ACS) into its
desired shape?

•

Should the collagen sponge be cut before or after the rhBMP-2 / sterile water
mixture is applied to it?

•

How much ACS is need for one implant?

•

4.0 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen sponges.
How much of the reconstituted rhBMP-2 is needed for just 1 collagen sponge? ½
of a collagen sponge? Etc.?
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•

How can a hole be created in the middle of the shaped sponge for the protruding
part of the implant when the rhBMP-2/ACS is placed on top of the TAD? (Note:
this is not applicable for this particular study, which solely focuses on the effect
of rhBMP-2/ACS placed underneath the implant).

•

Since the kit states that the wet collagen sponges must be used within 2 hours,
how many rats can undergo surgery within 2 hours with the assumption that the
sponges will be prepared before the surgeries begin?

Experimental procedure
•

Take a 10 mL syringe out into the field, and draw 8.4 mL of sterile water into the
syringe.

•

Inject 8.4 mL of sterile water into the buffer powder vial and swirl the vial to
ensure adequate mixing.

•

Open the collagen sponge package and take out one of the collagen sponges.

•

Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen
sponges, calculate the amount of mixture needed for 1 collagen sponge: 4 mL / 3
sponges = 1.33 mL / sponge.

•

Use another 10 mL syringe to withdraw 1.33 mL of reconstituted rhBMP-2 from
the vial.

•

Uniformly distribute 1.33 mL of reconstituted rhBMP-2 on 1 of the 2.5 cm x 5 cm
collagen sponges.

•

Allow the wet collagen sponge to stand for 15 minutes.
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•

After 15 minutes, use 2 different tools to cut the collagen sponge in the shape of
the implant.

•

Place a sample implant on the collagen sponge and used an x-acto knife to cut
around the outer edge of the implant.

•

Using another section of the collagen sponge, use a 1-hole punch to punch a hole
through the wet sponge.

•

Take out a second collagen sponge. This time, cut the non-wetted sponge with the
x-acto knife. Likewise, use the 1-hole punch on the non-wetted sponge.

Experimental Results and Conclusions
•

It is not necessary to separate the rhBMP-2 and sterile water into smaller vials.
As long as the reconstituted rhBMP-2 is refrigerated, it can be used at another
point in time. The effectiveness of the rhBMP-2 / sterile water mixture is not
compromised if it is not used all at once. The kit instructions state that the wet
collagen sponge must be used within 2 hours, but there is nothing stating that the
rhBMP-2 / sterile water mixture must be used within 2 hours.

•

The 1-hole punch is not a good tool for the purposes of this study because it
punches out a diameter that is smaller than the diameter of the implant for both
the non-wetted and wet sponge.

•

It is difficult to cut a circular shape with the x-acto knife on a wet sponge.
However, the x-acto knife works better when making straight cuts on the wet
sponge.
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•

It is difficult to cut a circular shape through a non-wetted sponge with the x-acto
knife, but easy to cut straight lines.

•

Cutting the non-wetted sponge is easier than cutting the wet sponge.

•

A 1.00 cm x 1.25 cm section (1/10 of 1 collagen sponge) of a non-wetted sponge
is needed for 1 implant. Once the sponge is wet, it can be shaped circularly to
follow the shape of the implant.

•

Use the following procedure to prepare the rhBMP-2/ACS for the implant:
1. Cut one non-wetted collagen sponge (2.5 cm x 5 cm) into 10 equal
sections (1.00 cm x 1.25 cm).

Figure B.5 Absorbable collagen sponge (figure not drawn to scale)

2. Apply the rhBMP-2 / sterile water mixture to a 1.00 cm x 1.25 cm section
of ACS. Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3
collagen sponges, the amount of mixture needed for 1 collagen sponge is 4
mL / 3 sponges = 1.33 mL / sponge. However, since one collagen sponge
is divided into 10 equal sections, 1/10 * 4/3 = 0.133 mL of the rhBMP-2 /
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sterile water mixture is needed per section. The syringe given in the kit is
a 10 mL syringe with increments of 0.2 mL. For better accuracy, use a
smaller syringe with smaller increments.
3. After waiting at least 15 minutes, place the wet collagen sponge on the rat
skull location where the implant will be placed, contouring the shape to fit
the circular shape of the implant. Set the implant over the wet collagen
sponge.
•

Since the wet collagen sponge must be used within 2 hours, only wet a 1.00 cm x
1.25 cm section of absorbable collagen sponge before each rat goes through
surgery.

•

Note: the collagen sponge pieces used during the actual surgery were different in
size than those used during the experimental phase. Specifically, 1 cm x 1 cm
pieces were used with 0.09 cc of reconstituted rhBMP-2.

B.3 Using One Rat to Determine the Following
1. Effectiveness of the type of anesthesia
A mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine,
10 mg/kg body weight of Xylazine) should be used for inducing general
anesthesia. The source used to determine these dosages is Lumb and Jones
Veterinary Anesthesia and Analgesia, 4th Ed. by W. J. Tranquilla. In addition, a
dose of Buprenorphine should be administered subcutaneously (0.01-0.05 mg/kg)
between the shoulder blades to mitigate pain [24]. The Ketamine/Xylazine
mixture provides approximately 30 minutes of effective anesthesia, and a ½ dose
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must be available to continue the anesthesia if the surgery takes longer than
expected. The Ketamine/Xylazine and Buprenorphine mixture works well
because emergence from anesthesia is smoother and it has a high factor of safety.
The reason why the Ketamine/Xylazine and Buprenorphine mixture is chosen
over an inhalant anesthetic, such as Halothane, is because Halothane requires that
the rats wear a mask during surgery. Unfortunately, this mask would interfere
with the surgical site, and therefore the Ketamine/Xylazine and Buprenorphine
mixture is the better choice.

2. Instrumentation needed
Tray for BMP-2 procedures, BMP-2 / ACS, syringes, forceps, fine
forceps, ultrafine forceps, weight boat, bench covers, sterile gowns, scrubs, mask,
rat gloves, nitrile gloves, sterile gloves, Ketamine, Xylazine, Buprenorphine,
shaver, depilatory cream (Veet®), Betadine solution, Petri dish with saline,
surgical drapes, scissors, scalpel, butyl cyanoacrylate / applicator, glass slab for
butyl, head cap, cotton gauze and swabs (both sterile and non-sterile), disposable
bag for blood and contaminated items, heating pad, recovery bin, etc.

3. Preparation / surgical procedures
A clean, uncluttered, and sanitized work surface should be used for prep
and surgery. Aseptic procedures must be followed:
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Pre-operative:
a. Sterilize instruments (using the method of heat sterilization) needed for
prep and surgery: tray for rhBMP-2 procedures, forceps, fine forceps,
ultrafine forceps, scissors, scalpel, butyl cyanoacrylate applicator, glass
slab for butyl, surgical drapes, syringes, gloves, Petri dish with saline,
cotton gauze, and cotton swabs.
b. Bring to surgical suite: sterile instruments mentioned above as well as
butyl cyanoacrylate, tupperware for weighing the rat, isolation mask and
cap, sterile gowns, bench covers, weight boat, and rat in the cage.
c. Obtain in surgical suite: Ketamine, Xylazine, Buprenorphine, scrubs, rat
gloves, nitrile gloves, sterile gloves, shaver, depilatory cream (Veet®),
Betadine solution, disposable bag for blood and contaminated items,
heating pad, recovery bin, and non-sterile cotton swabs and gauze.
d. In an area of the surgical suite, separate from the prep and surgery area, an
assistant must wash their hands, put on sterile gloves, and do the
following:
•

For a control TAD, take a 1 cm x 1 cm absorbable collagen
sponge with sterile forceps and wet it with 0.09 cc of saline
using a sterile syringe and a sterile tray. Let it stand for at least
15 minutes before use.

•

For an rhBMP-2 treated TAD, take a 1 cm x 1 cm absorbable
collagen sponge with sterile forceps and wet it with 0.09 cc of
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reconstituted rhBMP-2 using a sterile syringe and a sterile tray.
Let it stand for at least 15 minutes before use.
•

Meanwhile, continue with the following pre-operative
procedures.

e. Weigh the animal in a weight boat to determine the appropriate dosages of
Ketamine, Xylazine, and Buprenorphine. The amount of anesthesia given
to a rat is determined by the following criteria: 44 mg/kg body weight of
Ketamine, 10 mg/kg body weight of Xylazine, and 0.01 – 0.05 mg/kg
body weight of Buprenorphine. Record the dosages in the lab notebook.
f. Place a bench cover down on the table.
g. Put on rat gloves and grab the animal around the torso to administer the
anesthesia. Use a mixture of Ketamine and Xylazine (44 mg/kg body
weight of Ketamine, 10 mg/kg body weight of Xylazine) for inducing
general anesthesia. This will provide approximately 30 minutes of
effective anesthesia.
h. In addition, administer a dose of Buprenorphine subcutaneously (0.01 –
0.05 mg/kg body weight) between the shoulder blades. The
Ketamine/Xylazine and Buprenorphine mixture works well because
emergence from anesthesia is smoother and has a high factor of safety.
Place the rat in a chamber until the anesthesia takes effect and the animal
is down.
i. Throw out the bench cover and place a new one for prepping. An assistant
will start the prepping of the animal while the individual performing the
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surgery starts the surgical scrub and puts on a sterile gown to prepare for
surgery.
j. Assistant: put scrubs and nitrile gloves on for prepping procedures.
k. Take the rat out of the chamber and place on the bench cover. Use the
clippers provided in the surgical suite to shave the surgical site (rat’s
head). Then, apply depilatory cream on the surgical site. Wait a few
minutes for the depilatory cream to set. Rub the surgical site with a damp
2 x 2 cotton sponge to remove excess hair.
l. Pour Betadine antiseptic solution on a swab and apply it to the rat’s head
in a circular motion. Repeat a minimum of 3 times. Put the animal back
in the chamber.
m. Throw away the bench cover.
n. Disinfect the table to maintain a clean, uncluttered, and sanitized area.
Use gauze sponge to wipe it down.
o. Place down a new bench cover.
p. Put the rat down on the new bench cover.
q. Take off nitrile gloves and wash hands.
r. Take pre-sterile surgical packages with surgical drape and sterile
instruments, sterile gloves, isolation mask and cap, butyl
cyanoacrylate/applicator, glass slab, gauze, and cotton swabs and place
them on the table within reach of the individual performing surgery.
s. Put the heating pad in the microwave so it is ready to heat up once surgical
procedures are completed.
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t. Open up the sterile surgical package cover, and open up covering for
sterile instruments (without touching the actual instruments).
u. Once the “surgeon” has scrubbed and put on the sterile gown, he/she must
put on the sterile gloves and sit down to begin surgery.
v. The surgeon should now pull out the surgical drape from the sterile
surgical packages and place it on the animal. Use forceps and scissors to
cut drape at incision site. Use other forceps and scissors to do actual
incision (internal work).

Operative:
a. Begin surgery with sterile instruments and handle instruments aseptically.
b. Using the “tips-only” technique, make an incision along the line from the
middle of the eyes to the middle of the ears.
c. Once the incision is made, carefully fold back the periosteum using sterile
instruments (i.e. scalpel, forceps, etc.).
d. When the bony complex on the surface of the cranium is exposed, use
sterile forceps to pick up a titanium implant and contour it to fit the skull
shape. Use a sterile instrument to place the collagen sponge (wet with
saline or rhBMP-2) on the rat skull before placing the implant on top of it
and stabilizing it with butyl cyanoacrylate. Wait approximately 2 minutes
for the butyl cyanoacrylate to set.
e. While surgery is in progress, continually monitor the animal’s vital signs.
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f. Once the implant is stable, place as much of the periosteum over the
implant.
g. Use sterile forceps to hold the sides of skin at the incision site together
while an assistant closes the incision site using butyl cyanoacrylate. At
this point, have another assistant go to the microwave to heat up the
circulating heating pad for about 3-4 minutes to heat up to 37 degrees.

Post-Operative:
a. Remove the surgical drape.
b. Give the rat a subcutaneous injection of Buprenorphine (0.01 - 0.05
mg/kg).
c. Move the rat to a warm area (recovery bin) to return its body temperature
back to normal. In the recovery bin, place the rat on a blue bench cover,
above a heating pad, to allow it to recover. Return the animal to its
routine housing only after full recovery from anesthesia. Each rat will be
caged separately.
d. Buprenorphine (0.01 -0.05 mg/kg) should be administered 3 times a day
for 2 days as necessary for pain management. In the event of an infection,
the wound site will be cleaned 2 times/day with Betadine solution.
e. The rats will be visually inspected daily post-op for infection. A surgical
record (procedure, date, anesthesia dose, route of administration) will be
maintained.
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4. Surgical site to least elicit blood flow, angulations, and location of incision
The incision should be made in such a way that it elicits the least amount
of blood flow. In terms of the vascular structures in a rat, the common carotid
artery splits into the internal and external carotid arteries ventral to the auditory
bulla (bony capsule enclosing the middle and inner ear). The internal carotid
artery moves anteriorly to supply blood to the brain and the external carotid artery
moves anteriorly to supply blood to most of the structures of the head. To avoid
compromising the rat’s vascular system, an incision approximately 1 inch in
length should be made along the midline of the skull. The midline incision in the
scalp should be made using firm pressure to guarantee a clean cut in a single
stroke. The incision should be made from the area between the eyes to the area
between the ears. Then, once the incision is made, the periosteum can be carefully
removed. The periosteum can be pulled back and removed from the skull using
scalpel, forceps and scissors.

5. Implant contour, adhesion method, and incision site closure
The sites should be chosen such that the TAD follows the contour of the
skull in the best way possible. The TAD should be placed on the cranial bone
such that its distance from the cranial surface is as close as possible. Only one
implant can be successfully placed on the skull and covered with the periosteum.
The periosteum is too thin and does not sufficiently cover two implants at one
time. Therefore, only one implant will be used for each rat. Butyl cyanoacrylate
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will be used to ensure the adhesion of the implant to the bone and for closure of
the incision.

6. Implant size and protruding length
One 7 mm diameter TAD can fit on one rat skull. A protruding length of
2 mm on one side is sufficient enough for biomechanical testing and small enough
to prevent the rat from knocking it off. The surgical procedures should be purely
subcutaneous so that the protruding part of the implant will be under the skin.
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Appendix C
Surgery Checklist
Date____________

Rat Skull Surgery

Rat Information
Breed: _______________
Sex: ________________
Weight: ______________
Tag: _________________
Cage: ________________
Materials
Sterilized Instruments
___1. forceps
___2. fine forceps
___3. ultrafine forceps
___4. scissors
___5. scalpel
___6. cotton gauze
___7. cotton swabs
Bring to Surgical Suite
___8. sterile surgical drapes
___9. sterile syringes
___10. butyl cyanoacrylate/applicator/glass slab
___11. sterile gown, mask and cap
___12. bench covers
___13. weight boat
Obtained in Surgical Suite
___14. anesthesia (Ketamine and Xylazine)
___15. analgesic (Buprenorphine)
___16. scrubs
___17. rat gloves
___18. sterile gloves
___19. shaver
___20. depilatory cream (Veet®)
___21. Betadine solution
___22. disposable bag for blood and contaminated items
___23. heating pad
___24. recovery bin
___25. non-sterile cotton swabs
___26. non-sterile cotton gauze
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Initials____________

rhBMP-2/ACS or Saline/ACS Preparation
___27. Take a 1 cm x 1 cm absorbable collagen sponge and wet it with 0.09 cc of
reconstituted rhBMP-2 or saline (if control TAD).
___28. Let collagen sponge stand for at least 15 minutes before use.
Surgery Preparation
___29. Weigh animal in weight boat.
___30. Put on rat gloves and grab animal around torso to administer anesthesia. Use a
mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine, 10
mg/kg body weight of Xylazine). Record dosages in the lab notebook.
___31. Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg
body weight). Record dosage in the lab notebook.
___32. Place rat in chamber (anesthesia box) to let the anesthesia take effect.
___33. Surgeon: put on mask/cap, perform surgical scrub, and put on sterile gown and
gloves to prepare for surgery.
___34. Assistant: put scrubs and nitrile gloves on. Perform prepping procedures below.
___35. Place bench cover on table for preparation procedures.
___36. Take rat out of chamber and place on bench cover.
___37. Shave hair on surgical site (rat’s head) using clippers.
___38. Apply depilatory cream to surgical site and wait a few minutes.
___39. Rub surgical site with a damp 2 x 2 cotton sponge to remove excess hair.
___40. Apply Betadine solution on the rat’s head a minimum of 3 times in a circular
motion.
___41. Return rat to chamber.
___42. Throw away bench cover.
___43. Disinfect table. Use gauze to wipe it down.
___44. Place down a new bench cover.
___45. Put the rat down on the new bench cover.
___46. Take off nitrile gloves and wash hands.
___47. Place pre-sterile surgical packages (with sterile drape), sterile instruments, sterile
gloves, and isolation mask and cap on the table.
___48. Place heating pad in microwave so it is ready to heat up once surgery is done.
___49. Put on mask and cap.
___50. Open up sterile surgical packages (sterile drape and instruments) without
touching the inside of the sterile packages.
Surgery
___51. Surgeon: pull out sterile surgical drape from sterile package and put over rat.
Perform surgery procedures below.
___52. Use forceps and scissors to cut drape at incision site.
___53. Make an incision along the midline of the rat’s head, from the middle of the eyes
to the middle of the ears.
___54. Carefully fold back the periosteum using forceps.
___55. Use sterile forceps to pick up a titanium implant and contour it to fit the shape of
the skull.
___56. Use a sterile instrument to place the collagen sponge (wet with saline or rhBMP-
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2) on the rat skull before placing the TAD on top of it.
___57. Stabilize the TAD with butyl cyanoacrylate and let it set for approximately 2
minutes.
___58. Close the incision using butyl cyanoacrylate. At this time, have an assistant
microwave the heating pad for about 45 seconds.
Post-Surgical
___59. Remove surgical drape.
___60. Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg).
___61. Place rat in recovery bin, on a blue bench cover, above a heating pad to allow to
recover.
___62. Return rat to its routine housing only after full recovery from anesthesia. Each
rat will be caged separately.
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Appendix D
Anesthetics/Analgesics
D.1 Bottle Concentrations (mg/mL)
Ketamine HCl: 100 mg/mL
Xylazine: 20 mg/mL
Buprenorphine HCl: 0.3 mg/mL

D.2 Dosage (mg/kg of body weight)
Ketamine HCl: 44 mg/kg
Xylazine: 10 mg/kg
Buprenorphine HCl: 0.03 mg/kg

Table D.1 Number of mL administered of each drug based on weight
Weight of Rat (g) Weight of Rat (kg) Ketamine (mL) Xylazine (mL) Buprenorphine (mL)
200
0.200
0.088
0.100
0.020
205
0.205
0.090
0.103
0.021
210
0.210
0.092
0.105
0.021
215
0.215
0.095
0.108
0.022
220
0.220
0.097
0.110
0.022
225
0.225
0.099
0.113
0.023
230
0.230
0.101
0.115
0.023
235
0.235
0.103
0.118
0.024
240
0.240
0.106
0.120
0.024
245
0.245
0.108
0.123
0.025
250
0.250
0.110
0.125
0.025
255
0.255
0.112
0.128
0.026
260
0.260
0.114
0.130
0.026
265
0.265
0.117
0.133
0.027
270
0.270
0.119
0.135
0.027
275
0.275
0.121
0.138
0.028
280
0.280
0.123
0.140
0.028
285
0.285
0.125
0.143
0.029
290
0.290
0.128
0.145
0.029
295
0.295
0.130
0.148
0.030
300
0.300
0.132
0.150
0.030
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305
310
315
320
325
330
335
340

0.305
0.310
0.315
0.320
0.325
0.330
0.335
0.340

0.134
0.136
0.139
0.141
0.143
0.145
0.147
0.150
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0.153
0.155
0.158
0.160
0.163
0.165
0.168
0.170

0.031
0.031
0.032
0.032
0.033
0.033
0.034
0.034

Appendix E
Photographs of TAD Bone Coverage

Rat #
Rat 4

Table E.1 Visual inspection: TAD bone coverage
Control or rhBMP-2 treated
Bone Coverage
Bone coverage observed; however, data
Control, sponge on bottom
discarded as TAD was left in rat for over 6
weeks

Rat 8

Control, sponge on bottom

Rat 12

Sponge on bottom w/ rhBMP-2

Rat 13

Control, sponge on bottom
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Rat 14

Sponge on bottom w/ rhBMP-2

Rat 15

Sponge on bottom w/ rhBMP-2

Rat 16

Control, sponge on bottom

Rat 17

Sponge on bottom w/ rhBMP-2
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Rat 18

Sponge on bottom w/ rhBMP-2

Rat 20

Control, sponge on bottom

Rat 25

Sponge on bottom w/ rhBMP-2

No bone coverage observed – TAD stuck to
soft tissue

58

Appendix F
Failure Load Graphs from Biomechanical Testing

Rat 8
3
2.5

Load (N)

2
Series1

1.5
1
0.5
0

Figure F.1 Force-displacement curve for Rat 8

Rat 12
6
5

Load (N)

4
3
Series1
2
1
0
-1

Figure F.2 Force-displacement curve for Rat 12
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Rat 13
5
4.5
4

Load (N)

3.5
3
2.5

Series1

2
1.5
1
0.5
0

Figure F.3 Force-displacement curve for Rat 13

Rat 14
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14

Load (N)

12
10
Series1

8
6
4
2
0
-2

Figure F.4 Force-displacement curve for Rat 14
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Rat 15
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20
15
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10
5
0
-5

Figure F.5 Force-displacement curve for Rat 15

Rat 16
3.5
3

Load (N)

2.5
2
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1.5
1
0.5
0
-0.5

Figure F.6 Force-displacement curve for Rat 16
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Rat 17
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Figure F.7 Force-displacement curve for Rat 17

Rat 18
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0
-10

Figure F.8 Force-displacement curve for Rat 18
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Rat 25
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6
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0
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Figure F.9 Force-displacement curve for Rat 25
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